Drugs: musculoskeletal and joint diseases

Citations 11-20 of 309 total displayed.

Clinical and epidemiological research
A randomised controlled trial of spinal manipulative therapy in acute low back pain

P Jüni, M Battaglia, E Nüesch, G Hämmerle, P Eser, R van Beers, D Vils, J Bernhard, H-R Ziswiler, M Dähler, S Reichenbach, and P M Villiger
Ann Rheum Dis 2009 68: 1420 -1427; published online before print as 10.1136/ard.2008.093757 [Abstract] [Full text] [PDF] [Request Permissions]  

Editorials
Methotrexate: the gold standard without standardisation

Jonathan Kay and Rene Westhovens
Ann Rheum Dis 2009; 68: 1081-1082. [Extract] [Full text] [PDF] [Request Permissions]  

Clinical and epidemiological research
Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis

W Katchamart, J Trudeau, V Phumethum, and C Bombardier
Ann Rheum Dis 2009 68: 1105 -1112; published online before print as 10.1136/ard.2008.099861 [Abstract] [Full text] [PDF] [Request Permissions] [ Web Only Data ]  

Clinical and epidemiological research
Deoxyspergualin in relapsing and refractory Wegener’s granulomatosis

O Flossmann, B Baslund, A Bruchfeld, J W Cohen Tervaert, C Hall, P Heinzel, B Hellmich, R A Luqmani, K Nemoto, V Tesar, and D R W Jayne
Ann Rheum Dis 2009 68: 1125 -1130; published online before print as 10.1136/ard.2008.092429 [Abstract] [Full text] [PDF] [Request Permissions] [ Web Only Data ]  

Basic and translational research
Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance

E Kis, T Nagy, M Jani, É Molnár, J Jánossy, O Ujhellyi, K Német, K Herédi-Szabó, and P Krajcsi
Ann Rheum Dis 2009 68: 1201 -1207; published online before print as 10.1136/ard.2007.086264 [Abstract] [Full text] [PDF] [Request Permissions]  

Editorials
New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?

David L Scott and Andrew Cope
Ann Rheum Dis 2009; 68: 767-769. [Extract] [Full text] [PDF] [Request Permissions]  

Clinical and epidemiological research
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

R Fleischmann, J Vencovsky, R F van Vollenhoven, D Borenstein, J Box, G Coteur, N Goel, H-P Brezinschek, A Innes, and V Strand
Ann Rheum Dis 2009 68: 805 -811; published online before print as 10.1136/ard.2008.099291 [Abstract] [Full text] [PDF] [Request Permissions]  

Clinical and epidemiological research
Responsiveness of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis

T Uhlig, R Moe, S Reinsberg, T K Kvien, A Cieza, and G Stucki
Ann Rheum Dis 2009 68: 879 -884; published online before print as 10.1136/ard.2008.088708 [Abstract] [Full text] [PDF] [Request Permissions]  

Clinical and epidemiological research
Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group

M T Halpern, M A Cifaldi, and T K Kvien
Ann Rheum Dis 2009 68: 930 -937; published online before print as 10.1136/ard.2008.092734 [Abstract] [Full text] [PDF] [Request Permissions]  

Clinical and epidemiological research
Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI

J-P Raynauld, J Martel-Pelletier, P Bias, S Laufer, B Haraoui, D Choquette, A D Beaulieu, F Abram, M Dorais, É Vignon, J-P Pelletier, and and the Canadian Licofelone Study Group
Ann Rheum Dis 2009 68: 938 -947; published online before print as 10.1136/ard.2008.088732 [Abstract] [Full text] [PDF] [Request Permissions]